Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced a new publication in Molecular Therapy Advances summarizing the ...
Several pharmaceutical industry groups and companies have criticized the US Food and Drug Administration’s (FDA) recent guidance on potency assurance strategies for cell and gene therapies (CGTs) ...
Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision ...
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell ...
Abzena, a CDMO, said it has expanded its early- and late-phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, U.K., and San Diego, CA, development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results